Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Profit After Tax (2017 - 2025)

Sutro Biopharma's Profit After Tax history spans 9 years, with the latest figure at -$56.9 million for Q3 2025.

  • For Q3 2025, Profit After Tax fell 16.54% year-over-year to -$56.9 million; the TTM value through Sep 2025 reached -$216.8 million, down 74.88%, while the annual FY2024 figure was -$227.5 million, 112.99% down from the prior year.
  • Profit After Tax for Q3 2025 was -$56.9 million at Sutro Biopharma, down from -$11.5 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $31.1 million in Q4 2023 and bottomed at -$76.0 million in Q1 2025.
  • The 5-year median for Profit After Tax is -$38.5 million (2023), against an average of -$37.0 million.
  • The largest annual shift saw Profit After Tax surged 189.8% in 2023 before it tumbled 333.2% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$38.1 million in 2021, then increased by 9.26% to -$34.6 million in 2022, then soared by 189.8% to $31.1 million in 2023, then crashed by 333.2% to -$72.4 million in 2024, then rose by 21.51% to -$56.9 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Profit After Tax are -$56.9 million (Q3 2025), -$11.5 million (Q2 2025), and -$76.0 million (Q1 2025).